Ardelyx Inc (ARDX)
7.815
+0.02
(+0.32%)
USD |
NASDAQ |
May 17, 16:00
7.815
0.00 (0.00%)
After-Hours: 20:00
Ardelyx Revenue (Quarterly): 46.02M for March 31, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 46.02M |
| December 31, 2023 | 34.36M |
| September 30, 2023 | 56.39M |
| June 30, 2023 | 22.33M |
| March 31, 2023 | 11.37M |
| December 31, 2022 | 44.18M |
| September 30, 2022 | 4.986M |
| June 30, 2022 | 2.526M |
| March 31, 2022 | 0.468M |
| December 31, 2021 | 1.029M |
| September 30, 2021 | 1.173M |
| June 30, 2021 | 1.313M |
| March 31, 2021 | 6.582M |
| December 31, 2020 | 1.809M |
| September 30, 2020 | 2.713M |
| June 30, 2020 | 1.836M |
| March 31, 2020 | 1.213M |
| December 31, 2019 | 2.25M |
| September 30, 2019 | 3.013M |
| June 30, 2019 | 0.018M |
| March 31, 2019 | |
| December 31, 2018 | 0.085M |
| September 30, 2018 | 0.172M |
| Date | Value |
|---|---|
| June 30, 2018 | 0.03M |
| March 31, 2018 | 2.32M |
| December 31, 2017 | 42.00M |
| September 30, 2017 | |
| June 30, 2017 | |
| March 31, 2017 | |
| December 31, 2016 | |
| September 30, 2016 | |
| June 30, 2016 | |
| March 31, 2016 | |
| December 31, 2015 | |
| September 30, 2015 | |
| June 30, 2015 | 18.14M |
| March 31, 2015 | 5.883M |
| December 31, 2014 | 6.339M |
| September 30, 2014 | 7.598M |
| June 30, 2014 | 9.137M |
| March 31, 2014 | 8.55M |
| December 31, 2013 | 8.488M |
| September 30, 2013 | 6.593M |
| June 30, 2013 | 7.291M |
| March 31, 2013 | 6.556M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.018M
Minimum
Jun 2019
56.39M
Maximum
Sep 2023
12.28M
Average
2.620M
Median
Revenue (Quarterly) Benchmarks
| Nektar Therapeutics | 21.64M |
| Rigel Pharmaceuticals Inc | 29.53M |
| Vistagen Therapeutics Inc | 0.4114M |
| Adverum Biotechnologies Inc | -- |
| SeaStar Medical Holding Corp | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -26.52M |
| Total Expenses (Quarterly) | 70.70M |
| EPS Diluted (Quarterly) | -0.11 |
| Enterprise Value | 1.725B |
| Gross Profit Margin (Quarterly) | 84.51% |
| Profit Margin (Quarterly) | -57.62% |
| Earnings Yield | -3.71% |
| Normalized Earnings Yield | -3.713 |